Related references
Note: Only part of the references are listed.Screening Agents for Preventive Efficacy in a Bladder Cancer Model: Study Design, End Points, and Gefitinib and Naproxen Efficacy
Ronald A. Lubet et al.
JOURNAL OF UROLOGY (2010)
Structural basis for cofactor-independent dioxygenation of N-heteroaromatic compounds at the α/β-hydrolase fold
Roberto A. Steiner et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Cardiovascular Risks of Nonsteroidal Antiinflammatory Drugs in Patients After Hospitalization for Serious Coronary Heart Disease
Wayne A. Ray et al.
CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES (2009)
Oxygen pressurized X-ray crystallography:: Probing the dioxygen binding site in cofactorless urate oxidase and implications for its catalytic mechanism
Nathalie Colloc'h et al.
BIOPHYSICAL JOURNAL (2008)
Human pharmacology of naproxen sodium
Marta L. Capone et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2007)
Molecular determinants for the selective inhibition of cyclooxygenase-2 by lumiracoxib
Anna L. Blobaum et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Synthesis of urine drug metabolites:: glucuronic acid glycosides of phenol intermediates
Carl Johan Arewang et al.
CARBOHYDRATE RESEARCH (2007)
Structural and functional basis of cyclooxygenase inhibition
Anna L. Blobaum et al.
JOURNAL OF MEDICINAL CHEMISTRY (2007)
Cardiovascular risk and inhibition of cyclooxygenase - A systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase
Patricia McGettigan et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials
Patricia M. Kearney et al.
BMJ-BRITISH MEDICAL JOURNAL (2006)
The geminal dimethyl analogue of Flurbiprofen as a novel Aβ42 inhibitor and potential Alzheimer's disease modifying agent
N Stock et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2006)
2.0 Å structure of prostaglandin H2 synthase-1 reconstituted with a manganese porphyrin cofactor
K Gupta et al.
ACTA CRYSTALLOGRAPHICA SECTION D-STRUCTURAL BIOLOGY (2006)
Synthesis and biological activity of flurbiprofen analogues as selective inhibitors β-amyloid1-42 secretion
I Peretto et al.
JOURNAL OF MEDICINAL CHEMISTRY (2005)
Molecular basis of the time-dependent inhibition of cyclooxygenases by indomethacin
JJ Prusakiewicz et al.
BIOCHEMISTRY (2004)
Coot:: model-building tools for molecular graphics
P Emsley et al.
ACTA CRYSTALLOGRAPHICA SECTION D-STRUCTURAL BIOLOGY (2004)
A novel mechanism of cyclooxygenase-2 inhibition involving interactions with Ser-530 and Tyr-385
SW Rowlinson et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Synthesis and characterization of mononuclear iron silanethiolato complexes containing an unsupported Fe-S-Si bond system:: X-ray crystal structure of CpFe(CO)2SSiPh3 and its reaction with SO2
I Kovács et al.
INORGANIC CHEMISTRY (2003)
Determinants of the cellular specificity of acetaminophen as an inhibitor of prostaglandin H2 synthases
O Boutaud et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Structural analysis of NSAID binding by prostaglandin H2 synthase:: Time-dependent and time-independent inhibitors elicit identical enzyme conformations
BS Selinsky et al.
BIOCHEMISTRY (2001)
Different catalytically competent arrangements of arachidonic acid within the cyclooxygenase active site of prostaglandin endoperoxide H synthase-1 lead to the formation of different oxygenated products
ED Thuresson et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)